Thursday, 7 July 2022
  
Login

Australia's most trusted
source of pharma news

Thursday, 07 July 2022
Listen to this story 
News

New orphans lagging for Aust

Posted 27 May 2022 AM

Four new medicines for rare diseases recommended by Europe's advisory committee, the CHMP, are yet to make a local regulatory appearance, suggesting Australia may be far back on the waitlist.

Among the list is PTC Therapeutics gene therapy Upstaza for AADC deficiency, a fatal rare disorder, with children afflicted by the condition suffering physical, mental and behavioural symptoms, including seizures.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (7)

Sales & Customer Relations (26)

Access & Reimbursement (2)

Clinical & Medical, R&D (14)

Regulatory, Pharmacovigilance & QA (8)

Devices (1)

Other (29)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.